Abzyme Therapeutics is a privately held biopharmaceutical company that is harnessing the power of its proprietary antibody generation and optimization platform leveraged with the advantages of single domain antibodies to develop novel potent immunotherapeutics. 

Abzyme Therapeutics welcomes investors who bring a wealth of experience in drug discovery and development and provide valuable strategic support to the company.